Skip to main content
. 2021 Oct 5;2021:1622533. doi: 10.1155/2021/1622533

Table 4.

Multivariate logistic regression evaluating risk factors for death associated with COVID-19 during different periods of hospitalization.

Variable First week (days 0–7) Second week (days 8–14) Overall hospitalization
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Age (years) 1.04 (1.002–1.08) 1.08 (1.04–1.12) 1.05 (1.03–1.07)
Gender (male) 2.57 (0.7–9.41) 2.1 (0.7–6.7) 1.57 (0.86–2.85)
Cardiovascular comorbidity 4.77 (1.59–12.28) 8.65 (2.37–31.62) 6.17 (2.16–17.7) 9.53 (2.17–41.9) 3.75 (2.08–6.75) 3.1 (1.14–8.45)
Obesity (BMI>35) 1.06 (1.03–1.1) 3.63 (0.47–28.1) 2.87 (1.17–7.02)
Diabetes 1.02 (0.2–4.71) 0.86 (0.19–3.9) 1.1 (0.49–2.43)
Chronic liver disease 4.3 (1.03–15.75) 7.17 (1.51–34.16) 1.76 (0.48–6.4) 4.25 (1.72–10.5) 4.25 (0.95–19)
Time from symptoms to hospitalization (days) 0.99 (0.97–1.02) 0.98 (0.96–0.99) 0.99 (0.97–1.01)
Active smoker 11.35 (0.29–6.62) 1.44 (0.39–5.31) 2.7 (1.3–5.46) 6.45 (1.98–21)
WBC count (x109/L) on admission 1.15 (1.07–1.24) 1.17 (1.08–1.28) 1 (0.91–1.1) 1.07 (1.02–1.12)
WBC count (x109/L) at 1 week from admission 1.1 (0.95–1.17) 1.1 (1.04–1.18) 1.13 (1.04–1.23)
ALEx2 at admission 4.75 (1.55–14.62) 3.55 (1.05–12.05) 0.8 (0.25–2.5) 1.11 (0.62–2)
De novo-ALEx2 at 1 week after admission 6.3 (1.53–25.9) 6.09 (1.28–29) 2.79 (1.21–6.43) 2.93 (1.05–8.19)
Persistent-ALEx2 at 1 week after admission 9.57 (1.12–81.9) 4.98 (0.53–46.7) 3.24 (1.18–8.87) 3.73 (0.91–15.37)
Neutrophils/lymphocytes ratio 1.05 (1.01–1.08) 1 (0.95–1.05) 1.02 (0.99–1.05)
C-reactive protein (mg/L) 1 (0.99–1.003) 1 (0.99–1.01) 1.004 (1.001–1.006)
Procalcitonin (mg/L) 1.003 (0.91–1.09) 0.99 (0.91–1.09) 1.005 (0.97–1.05)
Serum creatinine (mg/dL) 1.22 (0.96–1.57) 1.37 (1.09–1.71) 1.24 (1.01–1.5)
Bilateral consolidation at admission 0.75 (0.2–2.77) 0.31 (0.04–2.4) 2.15 (1.12–4.13)

ALEx2, abnormal liver enzymes >2 times over the upper limit of normal; BMI, body mass index; WBC, white blood cells.